HR+ Metastatic Breast Cancer Targeted Therapy Profiles

This table helps compare the differences between the 3 FDA approved CDK4/6 inhibitors and a mTOR inhibitor used in treatment of patients with advanced breast cancer. Use this resource as a shared decision-making tool to help your patients understand the different therapy options and the differences between therapies so they can work with you to choose what is best for them.

The therapies included are:

• Abemaciclib
• Palbociclib
• Ribociclib
• Everolimus